Your prediction
Pros and Cons of Eagle Pharmaceuticals Inc in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Eagle Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | -1.850% | -9.402% | -4.505% | 12.766% | -1.852% | -39.429% | -58.431% |
| Corcept Therapeutics Inc. | 0.980% | -8.713% | 16.987% | 54.861% | 36.970% | 229.789% | 414.615% |
| Supernus Pharmaceuticals | -1.060% | -7.882% | -10.526% | 15.432% | -13.023% | 30.769% | 66.964% |
Comments
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) was downgraded by analysts at Piper Sandler from a "neutral" rating to an "underweight" rating.
Show more
Ratings data for EGRX provided by MarketBeat
